Wall Street Ends Mixed as Iran Tensions, OpenAI IPO Filing, and Inflation Concerns Weigh on Markets 
Dollar Near Two-Month High as Strong U.S. Jobs Data Boosts Fed Rate Hike Expectations 
Australian Consumer Sentiment Drops in June as Financial Concerns Weigh on Households 
Meta Partners With Reliance to Launch First AI-Powered Data Center in India 
Asian Stocks Rebound as AI and Chip Shares Recover; Easing Iran Tensions Boost Sentiment 
BoE Policymaker Alan Taylor Signals No Need for Interest Rate Hike Amid Iran War Inflation Risks 
Apollo Ends Pursuit of Bodycote, Withdraws £1.52 Billion Takeover Proposal 
Gordie Howe International Bridge Set to Open, Boosting U.S.-Canada Trade Links 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Vietnam Prioritizes Fiscal Stimulus as Monetary Policy Space Narrows 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
US Stocks Rebound as Iran Eases Military Operations; Tech Shares Lead Wall Street Recovery 
Oil Prices Rise as Iran-Israel Tensions Ease Following Trump-Led Ceasefire Push 
Italy’s ITA Airways Weighs Legal Action Against Pratt & Whitney Over Grounded Airbus Fleet 
BOJ Rate Hike Expectations Rise as Weak Yen and Strong U.S. Jobs Data Increase Pressure 
China Inflation Misses Forecast as Consumer Spending Stays Weak, Producer Prices Surge 
MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
GSK and Medicago are now closer to debuting the world's first plant-based COVID-19 vaccine after the completion of phase 3 clinical trial for the efficacy and safety of the immunization that they are developing.
This week, GlaxoSmithKline and Medicago announced getting positive results for their plant-based vaccine candidate for coronavirus. The product is Canadian-made, and it was found to be 71% effective after going through the third level of tests.
According to Canada's CTV News, Medicago Inc., the biotech company headquartered in Quebec, said their Phase 3 placebo-controlled study for their COVID-19 vaccine was conducted in over 24,000 subjects based in six countries.
The participants were 18 years old and older, and the outcome revealed the 71% effectiveness against all variants of coronavirus that were active at the time of the trial. The company further said that they did not find any serious safety issues as well.
The positive results were forwarded to regulators already so it can be authorized to release the world's very first plant-based COVID-19 vaccine worldwide. Just like the other available vaccines today, Medicago and GSK's candidate is also a two-dose injection.
Then again, while the biotech firm said its new vaccine was tested to be effective against the Delta variant but the trial did not include the Omicron variant because it was not yet circulating when the study began.
Currently, the vaccine producer is now processing documents and requirements for filing with health regulators in the U.K., U.S., and other nations. They will also forward the necessary data to World Health Organisation (WHO).
"This is an incredible moment for Medicago and for novel vaccine platforms. The results of our clinical trials show the power of plant-based vaccine manufacturing technology," Medicago chief executive officer and president Takashi Nagao said in a press release. "If approved, we will be contributing to the world's fight against the COVID-19 pandemic with the world's first plant-based vaccine for use in humans."
Finally, Nagao also expressed his gratitude to everyone who took part in the clinical trials, including its partners at GSK, Mitsubishi Tanabe Pharma Corporation, and the government of Canada and Quebec. He did not forget to thank Medicago's workers and shareholders, who are also committed to work on advancing vaccine science at a time when the world needs it.
